The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure

• Type: Article in International Scientific Journal
• Date: 2014

Authors

Lima, L (Author) Other; Oliveira, D (Author) Other; Tavares, A (Author) Other; Amaro, T (Author) Other; Cruz, R (Author) Other; Oliveira, MJ (Author) FCUP; Ferreira, JA (Author) Other; Santos, L (Author) Other

Journal

Title: Urologic Oncology: Seminars and Original Investigations

Vol. 32

Pages: 449-457

ISSN: 1078-1439

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 28 Citations

Scopus - 1 Citation

Other information

Authenticus ID: P-009-D4H

DOI: 10.1016/j.urolonc.2013.10.012

Abstract (EN): Objective: Bacillus Calmette-Guerin (BCG) immunotherapy is the gold standard treatment for superficial bladder tumors with intermediate/high risk of recurrence or progression. However, approximately 30% of patients fail to respond to the treatment. Effective BCG therapy needs precise activation of the type 1 helper cells immune pathway. Tumor-associated macrophages (TAMs) often assume an immunoregulatory M2 phenotype and may directly interfere with the BCG-induced antitumor immune response. Thus, we aim to clarify the influence of TAMs, in particular of the M2 phenotype in stroma and tumor areas, in BCG treatment outcome. Patients and methods: The study included 99 patients with bladder cancer treated with BCG. Tumors resected before treatment were evaluated using immunohistochemistry for CD68 and CD 163 antigens, which identify a lineage macrophage marker and a M2-polarized specific cell surface receptor, respectively. CD68(+) and CD163(+) macrophages were evaluated within the stroma and tumor areas, and high density of infiltrating cells spots were selected for counting. Hypoxia, an event known to modulate macrophage phenotype, was also assessed through hypoxia induced factor (HEF)-1 alpha expression. Results: Patients in whom BCG failed had high stroma-predominant CD163(+) macrophage counts (high stroma but low tumor CD163(+) macrophages counts) when compared with the ones with a successful treatment (71% vs. 47%, P = 0.017). Furthermore, patients presenting this phenotype showed decreased recurrence-free survival (log rank, P = 0.008) and a clear 2-fold increased risk of BCG treatment failure was observed in univariate analysis (hazard ratio = 2.343; 95% CI: 1.197-4.587; P = 0.013). Even when adjusted for potential confounders, such as age and therapeutic scheme, multivariate analysis revealed 2.6-fold increased risk of recurrence (hazard ratio = 2.627; 95% CI: 1.340-5.150; P = 0.005). High stroma-predominant CD163(+) macrophage counts were also associated with low expression of HIF-1 alpha in tumor areas, whereas high counts of CD163(+) in the tumor presented high expression of HIF-1 alpha in tumor nests. Conclusions: TAMs evaluation using CD163 is a good indicator of BCG treatment failure. Moreover, elevated infiltration of CD163(+) macrophages, predominantly in stroma areas but not in the tumor, may be a useful indicator of BCG treatment outcome, possibly owing to its immunosuppressive phenotype.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9